ELOCTA 3000 IU

国家: 以色列

语言: 英文

来源: Ministry of Health

有效成分:

COAGULATION FACTOR VIII

可用日期:

MEGAPHARM LTD

ATC代码:

B02BD05

药物剂型:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

组成:

COAGULATION FACTOR VIII 3000 IU

给药途径:

I.V

处方类型:

Required

厂商:

SWEDISH ORPHAN BIOVITRUM AB (PUBL), SWEDEN

治疗领域:

COAGULATION FACTOR VII

疗效迹象:

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

授权日期:

2022-08-31

资料单张

PATIENT PACKAGE INSERT IN ACCORDANCE WITH
THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986
This medicine is dispensed with a physician’s prescription only
ELOCTA 250, 500, 1000, 2000, 3000 IU
POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
THE MEDICINE’S NAME, FORM AND STRENGTH:
EACH VIAL OF POWDER CONTAINS:
RECOMBINANT HUMAN COAGULATION FACTOR VIII (EFMOROCTOCOG ALFA) 250 IU
RECOMBINANT HUMAN COAGULATION FACTOR VIII (EFMOROCTOCOG ALFA) 500 IU
RECOMBINANT HUMAN COAGULATION FACTOR VIII (EFMOROCTOCOG ALFA) 1000 IU
RECOMBINANT HUMAN COAGULATION FACTOR VIII (EFMOROCTOCOG ALFA) 2000 IU
RECOMBINANT HUMAN COAGULATION FACTOR VIII (EFMOROCTOCOG ALFA) 3000 IU
AFTER BEING DISSOLVED IN WATER FOR INJECTION:
1 ml of
ELOCTA 250 IU
contains approximately 83 IU (250 IU / 3 ml) of recombinant human
coagulation
factor VIII
1 ml of
ELOCTA 500 IU
contains approximately 167 IU (500 IU / 3 ml) of recombinant human
coagulation
factor VIII
1 ml of
ELOCTA 1000 IU
contains approximately 333 IU (1000 IU / 3 ml) of recombinant human
coagulation factor VIII
1 ml of
ELOCTA 2000 IU
contains approximately 667 IU (2000 IU / 3 ml) of recombinant human
coagulation factor VIII
1 ml of
ELOCTA 3000 IU
contains approximately 1000 IU (3000 IU / 3 ml) of recombinant human
coagulation factor VIII
Inactive and allergenic ingredients: see section 6 “Additional
information” and section 2 “Important
information about some of the medicine’s ingredients”.
READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE.
This leaflet contains concise
information about the medicine. If you have further questions, consult
with your physician or pharmacist.
This medicine has been prescribed to treat your illness. Do not pass
it on to others. It may harm them, even
if it seems to you that their illness is similar.
1.
WHAT IS THE MEDICINE INTENDED FOR?
ELOCTA
is intended for the treatment and prophylaxis of bleeding in patients
with hemophilia A (congenital
coagulation factor VIII deficiency).
THERAPEUTIC GROUP: ELOCTA
belongs to a class of bleed

产品特点

1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
ELOCTA 250 IU powder and solvent for solution for injection
ELOCTA 500 IU powder and solvent for solution for injection
ELOCTA 1000 IU powder and solvent for solution for injection
ELOCTA 2000 IU powder and solvent for solution for injection
ELOCTA 3000 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ELOCTA 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU (33.3 mcg/vial) efmoroctocog alfa.
ELOCTA contains approximately 83 IU/mL of recombinant human
coagulation factor VIII, efmoroctocog
alfa after reconstitution.
ELOCTA 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU (66.7mcg/vial) efmoroctocog alfa.
ELOCTA contains approximately 167 IU/mL of recombinant efmoroctocog
alfa after reconstitution.
ELOCTA 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU (133.3 mcg/vial) efmoroctocog
alfa.
ELOCTA contains approximately 333 IU/mL of recombinant efmoroctocog
alfa after reconstitution.
ELOCTA 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU (266.7 mcg/vial) efmoroctocog
alfa.
ELOCTA contains approximately 667 IU/mL of recombinant efmoroctocog
alfa after reconstitution.
ELOCTA 3000 IU powder and solvent for solution for injection
Each vial contains nominally 3000 IU (400mcg/vial) efmoroctocog alfa.
ELOCTA contains approximately 1000 IU/mL of recombinant efmoroctocog
alfa after reconstitution.
The potency (International Units (IU)) is determined using the
European Pharmacopoeia chromogenic assay.
The specific activity of ELOCTA is 4000-10200 IU/mg protein.
Efmoroctocog alfa (recombinant human coagulation factor VIII, Fc
fusion protein (rFVIIIFc)) has
1,890 amino acids. It is produced by recombinant DNA technology in a
human embryonic kidney (HEK) cell
line without the addition of any exogenous human- or animal-derived
protein in the cell culture proc